Phase three trials of the Novavax Covid-19 vaccine show it is 89.3% effective, according to the company.
The UK's ordered 60 million doses of the vaccine, which will be manufactured in north east England if approved by regulators,
Correspondent Olly Barratt says the studies suggest the vaccine will work on the 'UK variant' as well as the original coronavirus strain.
IN: 'Novavax...
OUT: ...doses.'
DUR: 53 seconds
The UK's ordered 60 million doses of the vaccine, which will be manufactured in north east England if approved by regulators,
Correspondent Olly Barratt says the studies suggest the vaccine will work on the 'UK variant' as well as the original coronavirus strain.
IN: 'Novavax...
OUT: ...doses.'
DUR: 53 seconds